Literature DB >> 3288862

High-level expression of c-H-ras1 fails to fully transform rat-1 cells.

M H Ricketts1, A D Levinson.   

Abstract

Rat-1 cells were transfected with plasmids encoding normal (Gly-12), nonactivated (Pro-12), and activated (Val-12 and Ile-12) p21H-ras in the presence of an amplifiable dihydrofolate reductase marker. The introduced DNA was amplified by selection in methotrexate to establish the relationship between p21H-ras expression and various hallmarks of cellular transformation. The maximum level of p21H-ras (Gly-12) consistent with cell viability was approximately 0.13% of total cell protein (approximately 60,000 molecules per cell); this is 44-fold greater than the level of the endogenous protein. The maximum tolerated level of a second nontransforming form of p21H-ras (pro-12) was about half of this. Amplification in Rat-1 cells of H-ras genes encoding the highly oncogenic Val-12 and Ile-12 forms of p21H-ras could not be achieved by methotrexate selection, providing strong evidence that synthesis of activated p21H-ras above a certain threshold (about 0.02% of total protein) in Rat-1 cells is incompatible with cell viability. Individual cell lines were isolated and their morphology, anchorage-independent growth, tumorigenicity, and response to and production of growth factors were studied. We report that cell lines expressing near-maximum tolerated levels of either the normal or pro-12 form of p21H-ras were not as transformed as cells expressing much more modest levels of the highly oncogenic (Val-12) form, suggesting that the complete elaboration of the transformed phenotype by ras depends, at least in part, on mutations that distinguish the cellular and viral proteins. We found that cells expressing elevated levels of the normal p21(H-ras) could be fully transformed by the activated (Val-12) form and that such cells continued to overexpress p21(H-ras) (Gly-12), arguing against a role for normal ras genes in suppression of the oncogenic potential of their mutationally activated counterparts.

Entities:  

Mesh:

Year:  1988        PMID: 3288862      PMCID: PMC363303          DOI: 10.1128/mcb.8.4.1460-1468.1988

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  48 in total

1.  Growth factors from murine sarcoma virus-transformed cells.

Authors:  J E de Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

2.  Suppression of malignancy by cell fusion.

Authors:  H Harris; O J Miller; G Klein; P Worst; T Tachibana
Journal:  Nature       Date:  1969-07-26       Impact factor: 49.962

Review 3.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

4.  Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.

Authors:  G J Todaro; C Fryling; J E De Larco
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Expression of a cellular oncogene during liver regeneration.

Authors:  M Goyette; C J Petropoulos; P R Shank; N Fausto
Journal:  Science       Date:  1983-02-04       Impact factor: 47.728

6.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

7.  Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction.

Authors:  A B Roberts; L C Lamb; D L Newton; M B Sporn; J E De Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

8.  Human cell hybrids: analysis of transformation and tumorigenicity.

Authors:  E J Stanbridge; C J Der; C J Doersen; R Y Nishimi; D M Peehl; B E Weissman; J E Wilkinson
Journal:  Science       Date:  1982-01-15       Impact factor: 47.728

9.  Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus.

Authors:  E H Chang; M E Furth; E M Scolnick; D R Lowy
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

10.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.

Authors:  G Urlaub; L A Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  12 in total

1.  Positive and negative modulation of H-ras transforming potential by mutations of phenylalanine-28.

Authors:  M H Ricketts; G A Durrheim; H M North; M J van der Merwe; A D Levinson
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

2.  A splicing enhancer in the 3'-terminal c-H-ras exon influences mRNA abundance and transforming activity.

Authors:  D Y Hwang; J B Cohen
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

3.  The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels.

Authors:  W Hammerschmidt; B Sugden; V R Baichwal
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  c-ras-Ha gene expression is regulated by insulin or insulinlike growth factor and by epidermal growth factor in murine fibroblasts.

Authors:  K H Lu; R A Levine; J Campisi
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

5.  Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors.

Authors:  A B Bianchi; C M Aldaz; C J Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Possible involvement of normal p21 H-ras in the insulin/insulinlike growth factor 1 signal transduction pathway.

Authors:  B M Burgering; A J Snijders; J A Maassen; A J van der Eb; J L Bos
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

7.  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Heather S Floyd; Joseph E Moore; Libyadda J Mosley; Ralph B D'Agostino; Mark J Pettenati; Mark Steven Miller
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-27       Impact factor: 4.219

8.  Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.

Authors:  S M Graham; A D Cox; G Drivas; M G Rush; P D'Eustachio; C J Der
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

9.  Development of an in vitro model of excess intracellular reactive oxygen species.

Authors:  K A Greer; M Pine; D L Busbee
Journal:  Age (Dordr)       Date:  2005-12-10

10.  Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.

Authors:  A D Cox; M M Hisaka; J E Buss; C J Der
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.